Skip to main content
REGN
NASDAQ Life Sciences

Trevogrumab Preserves 70% of Muscle Lost During GLP-1 Weight Loss in Phase 2

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$734.48
Mkt Cap
$75.618B
52W Low
$541
52W High
$859.34
52W Position info
36% above low
Off High info
15% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

REGN sits 36% above its 52-week low of $541.

Summary

Regeneron's Phase 2 COURAGE trial met its primary endpoint, showing trevogrumab preserved lean mass at 26 and 52 weeks when added to semaglutide. MRI substudy data showed up to 70% preservation of thigh muscle volume. A pre-specified subgroup analysis found greater benefit in patients with low lean mass at baseline. The company plans a Phase 2 trial in older adults with obesity and decreased muscle mass. This addresses a key concern with GLP-1 therapies and supports a differentiated obesity pipeline.

At the time of this announcement, REGN was trading at $734.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.6B. The 52-week trading range was $541.00 to $859.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

REGN - Latest Insights

REGN
Nov 08, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $900.00
Real-time Price: $950.03 info
Change: +$50.03 (+6%) info
Market Cap: $98.825B info
REGN
Oct 30, 2026, 12:34 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $910.52
Real-time Price: $950.03 info
Change: +$39.51 (+4%) info
Market Cap: $98.825B info
REGN
Oct 30, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $856.00
Real-time Price: $950.03 info
Change: +$94.03 (+11%) info
Market Cap: $98.825B info
REGN
Oct 30, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $835.00
Real-time Price: $950.03 info
Change: +$115.03 (+14%) info
Market Cap: $98.825B info
REGN
Oct 12, 2026, 12:06 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $764.45
Real-time Price: $950.03 info
Change: +$185.58 (+24%) info
Market Cap: $98.825B info